Boundless Bio Makes $100M IPO Debut on Nasdaq

Boundless Bio Secures $100 Million in IPO, Eyes Expansion in Precision Oncology

In a significant move marking its presence in the biotech sector, Boundless Bio has successfully garnered $100 million from its initial public offering (IPO), positioning itself as a formidable entity in precision oncology. The company set the price for its 6.25 million shares at $16 each, a figure that lies in the heart of its anticipated $15 to $17 range. This financial injection could potentially escalate to $115 million, should underwriters opt to acquire an additional 937,500 shares at the agreed price.